Prophylaxis against de novo hepatitis B or hepatitis B recurrence by vaccination for living-donor liver transplant recipients with hepatitis B-related disease: a pilot study

Prophylaxis against de novo hepatitis B or hepatitis B recurrence by vaccination for living-donor liver transplant recipients with hepatitis B-related disease: a pilot study - HBV vaccination for LDLT recipients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000259

Enrollment

Registered

2005-10-17

Start date

2005-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B, Living-donor liver transplantation recipient

Interventions

Hepatitis B vaccine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Living-donor liver transplantation recipient for hepatitis B related diseases. Living-donor liver transplantation recipient who received a graft from hepatitis B core antibody positive donor. Patients on prophylactic HBIG monotherapy. Negative for hepatitis B surface antigen, hepatitis e antigen, and hepatitis B virus DNA.

Exclusion criteria

Exclusion criteria: Positive for hepatitis C virus or human immunodeficiency virus. Patients on prophylactic lamivudine therapy.

Design outcomes

Primary

Measure	Time frame
Acquisition rate of active immunity following hepatitis B vaccination	—

Secondary

Measure	Time frame
Dose reduction of anti-HBs immunoglobulin infusion after active immunization	—

Countries

Japan

Contacts

Public ContactNoriyo Yamashiki

University of Tokyo Hospital The Artificial Organ and Transplantation Division, Department of Surgery

03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026